Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes

被引:57
|
作者
Caselli, R. J. [1 ,7 ]
Dueck, A. C. [7 ]
Locke, D. E. C. [7 ]
Sabbagh, M. N. [2 ,7 ]
Ahern, G. L. [4 ,7 ]
Rapcsak, S. Z. [4 ,7 ,8 ]
Baxter, L. C. [3 ,7 ]
Yaari, R. [5 ,7 ]
Woodruff, B. K. [7 ]
Hoffman-Snyder, C. [7 ]
Rademakers, R. [6 ]
Findley, S. [7 ]
Reiman, E. M. [4 ,5 ,7 ]
机构
[1] Mayo Clin Arizona, Dept Neurol, Scottsdale, AZ 85259 USA
[2] Banner Sun Hlth Res Inst, Sun City, AZ USA
[3] Barrow Neurol Inst, Phoenix, AZ 85013 USA
[4] Univ Arizona, Tucson, AZ USA
[5] Banner Alzheimer Inst, Phoenix, AZ USA
[6] Mayo Clin Jacksonville, Translat Genom Res Inst, Jacksonville, FL USA
[7] Arizona Alzheimers Consortium, Phoenix, AZ USA
[8] So Arizona VA Hlth Care Syst, Tucson, AZ USA
关键词
APOLIPOPROTEIN-E GENOTYPE; ALZHEIMERS-DISEASE; COGNITIVE IMPAIRMENT; ISCHEMIC-STROKE; DEMENTIA; AD; ASSOCIATION; INFARCTION; SMOKING;
D O I
10.1212/WNL.0b013e318211c3ae
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: To characterize the effects of cerebrovascular (CV) risk factors on preclinical memory decline in cognitively normal individuals at 3 levels of genetic risk for Alzheimer disease (AD) based on APOE genotype. Methods: We performed longitudinal neuropsychological testing on an APOE epsilon 4 enriched cohort, ages 21-97. The long-term memory (LTM) score of the Auditory Verbal Learning Test (AVLT) was the primary outcome measure. Any of 4 CV risk factors (CVany), including hypercholesterolemia (CHOL), prior cigarette use (CIG), diabetes mellitus (DM), and hypertension (HTN), was treated as a dichotomized variable. We estimated the longitudinal effect of age using statistical models that simultaneously modeled the cross-sectional and longitudinal effects of age on AVLT LTM by APOE genotype, CVany, and the interaction between the two. Results: A total of 74 APOE epsilon 4 homozygotes (HMZ), 239 epsilon 4 heterozygotes (HTZ), and 494 epsilon 4 noncarriers were included. APOE epsilon 4 carrier status showed a significant quadratic effect with age-related LTM decline in all models as previously reported. CVany was associated with further longitudinal AVLT LTM decline in APOE epsilon 4 carriers (p = 0.02), but had no effect in noncarriers. When epsilon 4 HTZ and HMZ were considered separately, there was a striking effect in HMZ (p < 0.001) but not in HTZ. In exploratory analyses, significant deleterious effects were found for CIG (p = 0.001), DM(p = 0.03), and HTN (p = 0.05) in APOE epsilon 4 carriers only that remained significant only for CIG after correction for multiple comparisons. Conclusion: CV risk factors influence age-related memory decline in APOE epsilon 4 HMZ. Neurology (R) 2011;76:1078-1084
引用
收藏
页码:1078 / 1084
页数:7
相关论文
共 50 条
  • [31] A-related memory decline in APOE ε4 noncarriers: Implications for Alzheimer disease
    Lim, Yen Ying
    Laws, Simon M.
    Villemagne, Victor L.
    Pietrzak, Robert H.
    Porter, Tenielle
    Ames, David
    Fowler, Christopher
    Rainey-Smith, Stephanie
    Snyder, Peter J.
    Martins, Ralph N.
    Salvado, Olivier
    Bourgeat, Pierrick
    Rowe, Christopher C.
    Masters, Colin L.
    Maruff, Paul
    NEUROLOGY, 2016, 86 (17) : 1635 - 1642
  • [32] Association of Cerebrospinal Fluid Ferritin Level With Preclinical Cognitive Decline in APOE-ε4 Carriers
    Ayton, Scott
    Faux, Noel G.
    Bush, Ashley I.
    JAMA NEUROLOGY, 2017, 74 (01) : 122 - 125
  • [33] Longitudinal Modeling of Age-Related Memory Decline and the APOE ε4 Effect
    Caselli, Richard J.
    Dueck, Amylou C.
    Osborne, David
    Sabbagh, Marwan N.
    Connor, Donald J.
    Ahern, Geoffrey L.
    Baxter, Leslie C.
    Rapcsak, Steven Z.
    Shi, Jiong
    Woodruff, Bryan K.
    Locke, Dona E. C.
    Snyder, Charlene Hoffman
    Alexander, Gene E.
    Rademakers, Rosa
    Reiman, Eric M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (03): : 255 - 263
  • [34] Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease
    Mormino, Elizabeth C.
    Betensky, Rebecca A.
    Hedden, Trey
    Schultz, Aaron P.
    Ward, Andrew
    Huijbers, Willem
    Rentz, Dorene M.
    Johnson, Keith A.
    Sperling, Reisa A.
    NEUROLOGY, 2014, 82 (20) : 1760 - 1767
  • [35] Preclinical cognitive decline in late middle-aged asymptomatic apolipoprotein E-e4/4 homozygotes: a replication study
    Caselli, RJ
    Osborne, D
    Reiman, EM
    Hentz, JG
    Barbieri, CJ
    Saunders, AM
    Hardy, J
    Graff-Radford, NR
    Hall, GR
    Alexander, GE
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2001, 189 (1-2) : 93 - 98
  • [36] Midlife cardiovascular risk factors, ApoE, and cognitive decline in elderly male twins
    Carmelli, D
    Swan, GE
    Reed, T
    Miller, B
    Wolf, PA
    Jarvik, GP
    Schellenberg, GD
    NEUROLOGY, 1998, 50 (06) : 1580 - 1585
  • [37] Preclinical memory profile in Alzheimer patients with and without allele APOE-epsilon4
    Estévez-González, A
    García-Sánchez, C
    Boltes, A
    Otermín, P
    Baiget, M
    Escartin, A
    del Rio, E
    Gironell, A
    Kulisevsky, J
    EUROPEAN NEUROLOGY, 2004, 51 (04) : 199 - 205
  • [39] APOE, attention, drinking, and health measures predict decline over 3 years in memory of healthy individiuals
    Kikuchi, LS
    Greenwood, PM
    Sunderland, T
    Putnam, K
    Levy, J
    Parasuraman, R
    JOURNAL OF COGNITIVE NEUROSCIENCE, 2005, : 238 - 238
  • [40] Cerebrovascular reactivity - predictive factor for cognitive decline in patients with cardiovascular risk factors
    Nicolae, H.
    Radici, R.
    Vulpe, G.
    Stefanescu, D.
    Panea, C.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 283 (1-2) : 291 - 291